CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale President and CEO sold 25,000 shares at an average $25.15 ($628,720)
- 144 Insider Sale of Securities
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Open-market sale COFO and Secretary sold 10,000 shares at $25.04 ($250,400)
- SC 13G Stake Amended Statement of Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Medical Officer sold 1,476 shares at $29.40 ($43,394)
- 4 Open-market sale Director sold 2,119 shares at $30.10 ($63,782)
- 4 Open-market sale COFO and Secretary sold 3,497 shares at $30.09 ($105,225)
- 4 Open-market sale President and CEO sold 33,815 shares at an average $30.08 ($1,017,243)
- 4 Open-market sale Chief Medical Officer sold 3,366 shares at an average $30.03 ($101,071)
- 4 Open-market sale President and CEO sold 28,433 shares at an average $29.28 ($832,515)
- SC 13G/A Stake Amended Statement of Ownership
Page 16 of 40 · 789 filings